Levodopa in the treatment of Parkinson's disease

Neurology

Volumn 55, Issue 11 SUPPL. 4, 2000, Pages

  Koller, W C ^a   Obeso, ^a   Olanow, ^a   Nutt, ^a   Schapira, ^a   Dingemanse, ^a   Lieberman, ^a   Stocchi, ^a   Waters, ^a   Jenner, ^a   Ra scol, ^a   Lewitt, ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); CATECHOL METHYLTRANSFERASE; LEVODOPA;

ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSKINESIA; HUMAN; MENTAL DISEASE; MOTOR DYSFUNCTION; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; VOMITING;

HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 0034642330     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Levodopa therapy in Parkinson's disease
2. The natural history of Parkinson's disease
3. 3,4-Dihydroxyphenylalanine and 6-hydroxytryptophan as reserpine antagonist
4. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system
5. Pharmacologic treatment of Parkinson's disease
6. Aromatic amino acids and modification of parkinsonism
7. Immediate-release and controlled-release carbidopa/levodopa in PD: A 5 year randomized multi-center study
8. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
9. The initial treatment of Parkinson's disease should begin with levodopa
10. Treatment of Parkinson's disease should begin with a dopamine agonist
11. An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines
12. Mechanism of actions of levodopa
13. Levodopa in the treatment of Parkinson's disease: A consensus meeting
14. Striatal mechanisms and pathologies of parkinsonian signs and motor complications
15. Motor fluctuations in Parkinson's disease: Pathogenic and therapeutic studies
16. Preventing levodopa-induced dyskinesia
17. Wearing-off fluctuations in Parkinson's disease: Contribution of postsynaptic mechanisms
18. The neuronal mechanism underlying levodopa-induced dyskinesias in Parkinson's disease
19. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
20. Surgery for levodopa-induced dyskinesias
21. Atypical antipsychotics in the treat ment of drug-induced psychosis in Parkinson's disease
22. Comparison of immediaterelease and controlled-release carbidopa/levodopa in Parkinson's disease: A multicenter 5-year study
23. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients
24. Liquid levodopa/carbidopa produces significant improvement in motor fluctuation without dyskinesia exacerbation